Accueil>>Signaling Pathways>> Metabolism>> IDO>>BMS-986242

BMS-986242

Catalog No.GC62496

Le BMS-986242 est un inhibiteur de l'indoleamine-2,3-dioxygénase 1 (IDO1) actif par voie orale, puissant et sélectif. BMS-986242 peut être utilisé pour la recherche sur le cancer.

Products are for research use only. Not for human use. We do not sell to patients.

BMS-986242 Chemical Structure

Cas No.: 1923844-48-7

Taille Prix Stock Qté
5 mg
405,00 $US
En stock
10 mg
720,00 $US
En stock
25 mg
1 485,00 $US
En stock
50 mg
2 340,00 $US
En stock
100 mg
3 600,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

BMS-986242 is an orally active, potent and selective indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor. BMS-986242 can be used for the research of cancer[1].

BMS-986242 is more prone to oxidative metabolism and less susceptible to glucuronidation. BMS-986242 shows IC50>25 μM for all targets except nAChR a1 (IC50=12.3 μM) and nAChR a7 (IC50>6 μM with ∼20 % max inhibition)[1].

BMS-986242 (3~30 mg/kg; p.o.; 0~24 hours) exhibits dose-proportional exposure and a statistically significant reduction in kynurenine concentration in the tumor at all three doses[1].

[1]. Cherney EC, et al. Discovery and Preclinical Evaluation of BMS-986242, a Potent, Selective Inhibitor of Indoleamine-2,3-dioxygenase 1. ACS Med Chem Lett. 2021;12(2):288-294. Published 2021 Jan 28.

Avis

Review for BMS-986242

Average Rating: 5 ★★★★★ (Based on Reviews and 20 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for BMS-986242

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.